The mechanism behind hormone dependent growth of breast cancer is presently not well understood. We show that the HES-1 protein level in the breast cancer cell lines T47D and MCF-7 is down regulated by 17b-estradiol treatment. This regulation could be reversed by addition of the anti-estrogens 4OH tamoxifen, raloxifen and Imperial Chemical Industries (ICI) 182,780. In T47D cells with inducible exogenous HES-1 expression, induced expression of HES-1 protein prevented the proliferative eect of 17b-estradiol and subsequent up regulation of proliferating cell nuclear antigen (PCNA). An inverse correlation between the HES-1 and PCNA protein levels respectively was found in colon cancer cell lines. These ®ndings point to a potential role of HES-1 as a tumor suppressor in epithelial cells, and as a mediator of 17b-estradiols proliferative eect on breast cancer cells. Oncogene (2000) 19, 5951 ± 5953.
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Keywords: proliferation; HES-1; PCNA; antiestrogen; 17b-estradiol Breast cancer is thought to result from estradiol stimulated proliferation of preinitiated epithelial cell clones (Ferguson and Davidson, 1997) . Few downstream target genes for 17b-estradiol in the context of estrogen mediated eects on proliferation are known. Where two examples are c-myc (Kyo et al., 1999) and cyclin D1 (Hong et al., 1998) . Here we show that the basic helix ± loop ± helix (bHLH) factor HES-1 (Feder et al., 1993) constitutes another target for estradiol signaling. This factor has been shown to repress neuronal dierentiation when expressed ectopically in the mammalian central nervous system (CNS) or chick retinal cells during development (Ishibashi et al., 1994; Tomita et al., 1996) . HES-1 involvement in neuronal dierentiation has also been shown in other systems, such as the rat cell line PC12, where exogenous expression of HES-1 delays dierentiation induced by NGF (StroÈ m et al., 1997) and, in embryonic day-17 hippocampal neurons in culture where down regulation of endogenous HES-1 has been shown to be critical for neuronal dierentiation (Castella et al., 1999) .
During development HES-1 is an eector of notch signaling. There are four mammalian forms of notch receptors, and the corresponding ligands in vertebrates are Delta1, Delta3, Jagged1 and Jagged2. Notch receptors are involved in control of cellular response to developmental cues which are specifying cell fate (Artavanis-Tsakonas et al., 1999) .
In Drosophila the HES-1 homologue, hairy recruits the co-repressor groucho, and has been shown to repress transcription of genes involved in determining neuronal fate (Fisher and Caudy, 1998) . The mammalian homologues to groucho are transducinlike Enhancer of split (TLE) proteins 1 ± 4 (Stifani et al., 1992) , with individually dierent tissue distributions, where TLE1 is the most widely expressed form.
In addition to the nervous system HES-1 is also found in lung, kidney, intestine (Sasai et al., 1992) , pancreas where notch signaling controls dierentiation (Apelqvist et al., 1999) and T-cell precursors, where lack of HES-1 expression leads to drastically decreased number of T-cells (Tomita et al., 1999) . This implies that HES-1 is important for keeping cells non dierentiated and proliferating. The same seems to be true for the nervous system where premature neurogenesis is seen in the HES-1 knockout mouse (Ishibashi et al., 1995) .
HES-1 is also expressed in non-small lung cancer but is absent in small cell lung cancer (Chen et al., 1997) . Small cell lung cancer is one of the most severe forms of lung cancer that proliferates and metastasises very rapidly, perhaps indicating that lack of HES-1 expression correlates to a more aggressive form of cancer.
We investigated expression of HES-1 in epithelial cell types such as breast and colon cancer cell lines using antibodies to HES-1. Expression was found in three out of three breast cancer cell lines, and was high in three out of ®ve colon cancer cell lines. The expression level varies somewhat between the dierent breast cancer cell lines being highest in MCF-7 followed by T47D and MDA-MB-231. In the case of the colon cancer cell lines expression of HES-1 occurs in the order LoVo, HT29, SW480, HCT116 and Colo320. In the last mentioned cell line HES-1 expression is virtually absent (Figure 1a) . The mechanism behind the dierent expression levels in the cell lines are currently unknown.
In a study of the breast cancer cell lines we found that 17b-estradiol suppressed the HES-1 protein level in T47D and MCF-7 cells. While MDA-MB-231 cells lacked 17b-estradiol mediated suppression of HES-1 (Figure 1b) this is an indication that the estrogen receptor alpha (ERa) is needed for this regulation since these cells lack ERa (Friedl and Jordan, 1994 (Figure 1c) . The eects on HES-1 expression by antiestrogens further support involvement of the estrogen receptor in HES-1 regulation by 17b-estradiol.
We next used tet-o T47D cells stably transfected with a vector containing¯ag epitope fused HES-1 the expression of which could be tetracycline regulated, in order to study if induced expression of exogenous HES-1 could aect proliferation. When cells were grown in the presence of tetracycline and thus without induced HES-1 expression, a normal twofold stimulation of proliferation by 17b-estradiol treatment was observed. However, in the absence of tetracycline with induced HES-1 expression no 17b-estradiol stimulated proliferation was obtained, strongly suggesting that HES-1 protein level needs to be down regulated for proliferation to increase following treatment with 17b-estradiol (Figure 2a) . The proliferation marker proliferating cell nuclear antigen (PCNA) was upregulated 1.4-and 1.9-fold for clone 1 and 2 respectively by estrogen in the absence of exogenous HES-1 expression, but in the presence of exogenous HES-1 suppression of the expression level was observed (Figure 2b ). This suggests that PCNA is a direct or indirect target gene for HES-1. Additional evidence for this is that suppression of PCNA expression by HES-1 have recently been shown in PC12 cells (Castella et al., 2000) . In the absence of expression of exogenous HES-1, 17b-estradiol regulation of endogenous HES-1 was observed (Figure 2b ) con®rming that the cells had not lost their ability to respond to 17b-estradiol by clonal selection, and that the 17b-estradiol stimulated proliferation is likely mediated by HES-1. Two control cell lines stably transfected with the tetracycline regulated expression vector lacking HES-1 showed 17b-estradiol stimulated proliferation (Figure 2a ), con®rming that Figure 1 (a) Western blotting of nuclear extracts from breast and colon cancer cell lines, respectively, using antibody to HES-1; 100 mg of nuclear protein was used. As control in vitro translated HES-1 (IVT HES-1) was used. (b) Regulation of HES-1 by 17b-estradiol in breast cancer cell lines; 50 mg of nuclear extract protein was used. (c) 17b-estradiol regulation of HES-1 in T47D cells opposed by antagonists to the estrogen receptor; 50 mg of nuclear protein was used. For production of antibodies two peptides with identical sequence to HES-1 protein were synthesized and simultaneously injected into one rabbit (Genosys). The peptides were CMEKNSSSPVAATPASVNTTP-DKPKTASEHR and CSGTSVGPNAVSPSSGSSLTADSMWR-PWRN. For Western blot, nuclear extract was separated on a 12% SDS ± PAGE and blotting was performed according to standard protocols (Harlow and Lane, 1988 ) HES-1 antibody was used at 1 : 1000. The PCNA (C-10) antibody was from Santa Cruz and used at 1 : 1000. Donkey anti rabbit and sheep anti mouse IgG HRP conjugated antibody (Amersham) was used at 1 : 10 000. Antibody binding was visualized using ECL, Super Signal (Pierce) Figure 2 Proliferation assay of T47D cells stably transfected with tetracycline regulated¯ag-HES-1 expression. (a) Relative proliferation of two dierent clones HES-1(1) and HES-1(2) with inducible¯ag-HES-1 expression, and two control clones. Tetracycline (tet) at 1 mg/ml and 17b-estradiol (E2) at 10 nM were used when stated. (b) Western blotting of endogenous HES-1 and¯ag-HES-1 expression in HES-1(1) and HES-1(2) cell lines with antibody against HES-1, 50 mg of nuclear protein was used. PCNA (Santa Cruz, antibody PC10) Western blotting was done on same extracts but 25 mg of nuclear protein was used. The level of PCNA expression was evaluated relative to expression of HDAC1 (Santa Cruz, by densiometric scanning using a Macintosh computer and the public domain NIH Image program (developed at the US National Institutes of Health and available on the Internet at http://rsb.info.gov/nih-image/). For proliferation determination a kit from BioThema (Lundin, 2000) was used. The cells were grown on 24 well plates at approximately 1000 cells/well. Treatment with hormone was in phenol-red free medium supplemented with 10% DCC treated fetal calf serum. After hormone treatment for 5 days the medium was removed and 200 ml 5% TCA was added to the well followed by 1.8 ml 80 mM Tris-acetate 2 mM EDTA pH 7.8. Twenty ml of this mixture was removed to 140 ml of the Tris-acetate buer. Luciferase activity was measured using a Berthold luminometer HES-1 mediates the proliferative effect of 17b-estradiol A Stro Èm et al expression of the VP16 fused transactivator (a component of the tetracycline regulated expression system) did not inhibit 17b-estradiol stimulated proliferation. We used colon cancer cell lines to investigate if there is a correlation between HES-1 expression and a marker of proliferation also in another epithelial cell line than breast cancer. Western blotting with antibodies against HES-1 and PCNA gave an inverted correlation between the protein levels of the two factors, indicating that lack of HES-1 allows a higher expression of PCNA (Figure 3) .
The antiproliferative strategy of current breast cancer therapy aimed at inhibiting ERa activity, seems to operate mechanistically by prevention of HES-1 down regulation, since expression of exogenous HES-1 substituting the downregulated endogenous HES-1 prevents 17b-estradiol mediated increase of proliferation in T47D cells (Figure 2a) . A model of this regulation is shown in Figure 4 .
Our results suggest that HES-1 works not only as a regulator of dierentiation, as shown before, but also by controlling proliferation. Perhaps the expression level of HES-1 determines the rate of cellular proliferation and also prevents dierentiation in the nervous system. However, in epithelial cells HES-1 might have a more pronounced role as a regulator of proliferation in response to dierent cellular stimulators. HES-1 as a target for hormone stimulated proliferation in cancer makes HES-1 interesting as a potential target for cancer treatment. 
